Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)
Trial to Reduce Cardiovascular Events With Aranesp® Therapy
Sponsor: Amgen
This PHASE3 trial investigates Anemia and Diabetes Mellitus and is currently completed. Amgen leads this study, which shows 9 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2022 — Dec 2022 [monthly]
Completed PHASE3
-
Dec 2021 — Sep 2022 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Aug 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.